IL43764A - Oral corticosteroid preparations - Google Patents
Oral corticosteroid preparationsInfo
- Publication number
- IL43764A IL43764A IL43764A IL4376473A IL43764A IL 43764 A IL43764 A IL 43764A IL 43764 A IL43764 A IL 43764A IL 4376473 A IL4376473 A IL 4376473A IL 43764 A IL43764 A IL 43764A
- Authority
- IL
- Israel
- Prior art keywords
- corticosteroid
- layer
- prednisolone
- soluble
- corticosteroids
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims description 25
- 230000028327 secretion Effects 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000002552 dosage form Substances 0.000 claims abstract 3
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims abstract 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims abstract 2
- 229960000258 corticotropin Drugs 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 229960001334 corticosteroids Drugs 0.000 claims description 19
- 230000006978 adaptation Effects 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 3
- 230000033764 rhythmic process Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 12
- 210000004051 gastric juice Anatomy 0.000 abstract description 11
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract description 11
- 229960005205 prednisolone Drugs 0.000 abstract description 10
- 238000000576 coating method Methods 0.000 abstract description 9
- 230000009471 action Effects 0.000 abstract description 7
- 239000011248 coating agent Substances 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 4
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 abstract description 3
- 229960003290 cortisone acetate Drugs 0.000 abstract description 3
- 150000002148 esters Chemical class 0.000 abstract description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract description 2
- 230000027288 circadian rhythm Effects 0.000 abstract description 2
- 238000013270 controlled release Methods 0.000 abstract description 2
- 229960004544 cortisone Drugs 0.000 abstract description 2
- 229960000890 hydrocortisone Drugs 0.000 abstract description 2
- 229960004618 prednisone Drugs 0.000 abstract description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract description 2
- 230000001360 synchronised effect Effects 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 101800000414 Corticotropin Proteins 0.000 abstract 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 abstract 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 abstract 1
- 235000021152 breakfast Nutrition 0.000 abstract 1
- 229960004584 methylprednisolone Drugs 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000008298 dragée Substances 0.000 description 21
- 239000013543 active substance Substances 0.000 description 9
- 230000002060 circadian Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 235000019759 Maize starch Nutrition 0.000 description 4
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960002800 prednisolone acetate Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000004922 lacquer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229940051868 antimigraine drug corticosteroid derivative Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2260384A DE2260384C3 (de) | 1972-12-09 | 1972-12-09 | Oral zu applizierendes Corticosteroid-Präparat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL43764A0 IL43764A0 (en) | 1974-03-14 |
| IL43764A true IL43764A (en) | 1977-03-31 |
Family
ID=5864005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL43764A IL43764A (en) | 1972-12-09 | 1973-12-06 | Oral corticosteroid preparations |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS4986527A (enExample) |
| KR (1) | KR780000243B1 (enExample) |
| AT (1) | AT345983B (enExample) |
| BE (1) | BE808442A (enExample) |
| CA (1) | CA1027864A (enExample) |
| DE (1) | DE2260384C3 (enExample) |
| FR (1) | FR2209585B1 (enExample) |
| GB (1) | GB1458676A (enExample) |
| HU (1) | HU171907B (enExample) |
| IE (1) | IE38614B1 (enExample) |
| IL (1) | IL43764A (enExample) |
| NL (1) | NL7316585A (enExample) |
| ZA (1) | ZA739327B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1392321B1 (en) * | 2001-03-15 | 2010-08-18 | Soligenix, Inc. | Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
| SE0401031D0 (sv) * | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
| WO2005102287A2 (en) | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
| SG174583A1 (en) * | 2009-04-07 | 2011-10-28 | Duocort Pharma Ab | Improved glucocorticoid therapy |
| RS59241B1 (sr) | 2009-10-01 | 2019-10-31 | Adare Development I L P | Kortikosteroidne kompozicije za oralnu administraciju |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB862376A (en) * | 1957-10-10 | 1961-03-08 | Pfizer & Co C | Sustained release pharmaceutical tablet |
-
1972
- 1972-12-09 DE DE2260384A patent/DE2260384C3/de not_active Expired
-
1973
- 1973-12-03 FR FR7343036A patent/FR2209585B1/fr not_active Expired
- 1973-12-03 KR KR7302039A patent/KR780000243B1/ko not_active Expired
- 1973-12-04 NL NL7316585A patent/NL7316585A/xx not_active Application Discontinuation
- 1973-12-06 CA CA187,580A patent/CA1027864A/en not_active Expired
- 1973-12-06 IL IL43764A patent/IL43764A/en unknown
- 1973-12-06 HU HU73HO00001633A patent/HU171907B/hu unknown
- 1973-12-07 ZA ZA739327A patent/ZA739327B/xx unknown
- 1973-12-07 AT AT1026773A patent/AT345983B/de active
- 1973-12-07 IE IE2216/73A patent/IE38614B1/xx unknown
- 1973-12-08 JP JP48137285A patent/JPS4986527A/ja active Pending
- 1973-12-10 GB GB5709073A patent/GB1458676A/en not_active Expired
- 1973-12-10 BE BE138701A patent/BE808442A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE2260384A1 (de) | 1974-06-12 |
| GB1458676A (en) | 1976-12-15 |
| IL43764A0 (en) | 1974-03-14 |
| DE2260384B2 (de) | 1979-04-12 |
| FR2209585B1 (enExample) | 1977-09-02 |
| KR780000243B1 (en) | 1978-07-01 |
| AU6328073A (en) | 1975-06-12 |
| IE38614L (en) | 1974-06-09 |
| ATA1026773A (de) | 1978-02-15 |
| ZA739327B (en) | 1974-10-30 |
| DE2260384C3 (de) | 1979-11-29 |
| NL7316585A (enExample) | 1974-06-11 |
| HU171907B (hu) | 1978-04-28 |
| BE808442A (fr) | 1974-06-10 |
| JPS4986527A (enExample) | 1974-08-19 |
| IE38614B1 (en) | 1978-04-26 |
| CA1027864A (en) | 1978-03-14 |
| FR2209585A1 (enExample) | 1974-07-05 |
| AT345983B (de) | 1978-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4066756A (en) | Therapeutic compositions of 1,3-bis(2-carboxychromon-5-yloxyl)propan-2-ol and aspirin or indomethacin | |
| US4587118A (en) | Dry sustained release theophylline oral formulation | |
| US4308251A (en) | Controlled release formulations of orally-active medicaments | |
| US6015577A (en) | Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation | |
| US6117450A (en) | Method of making a perorally administered solid drug with controlled effective ingredient delivery | |
| US5260068A (en) | Multiparticulate pulsatile drug delivery system | |
| US4806361A (en) | Medicaments in sustained release unit dose form | |
| CA2815959C (en) | Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms | |
| SK37699A3 (en) | Oral delayed immediate release formulation and method of preparation therefor | |
| KR20060015528A (ko) | 정해진 핵 위치를 가지는 서방성 정제 | |
| RS20090134A (sr) | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva | |
| US2970082A (en) | Aluminum nicotinate compositions for hypercholesteremia | |
| JP2967492B2 (ja) | 腸内適所放出経口製剤 | |
| IL43764A (en) | Oral corticosteroid preparations | |
| JPH0443052B2 (enExample) | ||
| DK158599B (da) | Allergenpraeparat til oral administration | |
| CA1099641A (en) | Pharmaceutical composition containing chromone derivatives | |
| BG65204B1 (bg) | Фармацевтичен състав, фармацевтичен кит и използването им като противозачатъчно средство | |
| US4042698A (en) | Treatment of myasthenia gravis and oral medication therefor | |
| JPS5845403B2 (ja) | 補酵素ｑを主成分とする膵機能亢進剤 | |
| JPS63145232A (ja) | コレステロール代謝変化治療用薬剤 | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона | |
| TWI744858B (zh) | 治療精神疾病之控釋藥物組合物和方法 | |
| CA2166427A1 (en) | Use of bile acids for preparing medicaments for the treatment of skin diseases | |
| JPS63162623A (ja) | ウラピジルおよび薬理学的に許容可能な脂肪族ジカルボン酸を含有する遅効ペレツト形の医薬 |